The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

@article{Moran2013TheTO,
  title={The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.},
  author={Amy E Moran and Magdalena Kovacsovics-Bankowski and Andrew D. Weinberg},
  journal={Current opinion in immunology},
  year={2013},
  volume={25 2},
  pages={230-7}
}
T cell-mediated rejection of tumors requires signals from the T cell receptor and co-stimulatory molecules to license effector functions of tumor-antigen specific T cells. There is also an array of immune suppressive mechanisms within the tumor microenvironment that can suppress anti-tumor immunity. The use of monoclonal antibodies to overcome this suppression and/or enhance tumor-antigen specific T cell responses has shown promise in clinical trials. In particular, targeting co-stimulatory… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 49 extracted citations

Similar Papers

Loading similar papers…